Standout Papers

Adjuvant imatinib mesylate after resection of localised, primary gastrointest... 2005 2026 2012 2019 941
  1. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial (2009)
    Ronald P. DeMatteo, Karla V. Ballman et al. The Lancet
  2. NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors (2010)
    George D. Demetri, Margaret von Mehren et al. Journal of the National Comprehensive Cancer Network
  3. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033 (2008)
    Charles D. Blanke, Cathryn Rankin et al. Journal of Clinical Oncology
  4. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation (2005)
    Cristina R. Antonescu, Peter Besmer et al. Clinical Cancer Research
  5. Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor (2010)
    James E. Butrynski, David R. D’Adamo et al. New England Journal of Medicine
  6. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial (2015)
    George D. Demetri, Margaret von Mehren et al. Journal of Clinical Oncology
  7. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor (2008)
    Michael C. Heinrich, Robert G. Maki et al. Journal of Clinical Oncology
  8. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial (2016)
    Patrick Schöffski, Sant P. Chawla et al. The Lancet
  9. Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002 (2007)
    Robert G. Maki, J. Kyle Wathen et al. Journal of Clinical Oncology
  10. Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial (2002)
    Martee L. Hensley, Robert G. Maki et al. Journal of Clinical Oncology
  11. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model (2017)
    Elizabeth G. Demicco, Michael J. Wagner et al. Modern Pathology

Immediate Impact

10 by Nobel laureates 7 from Science/Nature 69 standout
Sub-graph 1 of 20

Citing Papers

Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
Ewing’s Sarcoma
2021 Standout
7 intermediate papers

Works of Robert G. Maki being referenced

R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study
2011
High prevalence of CIC fusion with double‐homeobox (DUX4) transcription factors in EWSR1 ‐negative undifferentiated small blue round cell sarcomas
2011
and 3 more

Author Peers

Author Last Decade Papers Cites
Robert G. Maki 17885 9578 7745 377 25.7k
Samuel Singer 16327 7981 6883 326 28.2k
George D. Demetri 23206 10951 16610 342 37.2k
Raf Sciot 11789 5126 4398 544 23.7k
Brian P. Rubin 10841 4148 7150 273 18.7k
M. van Glabbeke 17691 15322 4637 195 34.8k
Jason L. Hornick 11221 8067 2279 479 24.0k
Angelo Paolo Dei Tos 10249 5978 1854 432 16.0k
Michael C. Heinrich 17093 5598 16713 373 31.5k
Christopher L. Corless 16635 5773 14883 318 30.3k
Jonathan A. Fletcher 10823 5416 8303 202 22.9k

All Works

Loading papers...

Rankless by CCL
2026